S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:RGEN

Repligen (RGEN) Stock Forecast, Price & News

$154.53
-0.10 (-0.06%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$150.09
$158.00
50-Day Range
$141.93
$191.43
52-Week Range
$137.21
$327.32
Volume
247,800 shs
Average Volume
508,797 shs
Market Capitalization
$8.41 billion
P/E Ratio
61.08
Dividend Yield
N/A
Beta
0.98
30 days | 90 days | 365 days | Advanced Chart
Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

Repligen logo

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,852
Year Founded
1981

Sales & Book Value

Annual Sales
$670.53 million
Cash Flow
$4.07 per share
Book Value
$32.45 per share

Profitability

Net Income
$128.29 million
Pretax Margin
24.43%

Debt

Price-To-Earnings

Miscellaneous

Free Float
53,830,000
Market Cap
$8.41 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/27/2022
Today
5/22/2022
Next Earnings (Estimated)
7/26/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

128th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

19th out of 210 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Repligen (NASDAQ:RGEN) Frequently Asked Questions

Is Repligen a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen
or view top-rated stocks.

Are investors shorting Repligen?

Repligen saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 2,780,000 shares, an increase of 21.4% from the April 15th total of 2,290,000 shares. Based on an average daily trading volume, of 519,600 shares, the days-to-cover ratio is currently 5.4 days. Currently, 5.4% of the company's stock are sold short.
View Repligen's Short Interest
.

When is Repligen's next earnings date?

Repligen is scheduled to release its next quarterly earnings announcement on Tuesday, July 26th 2022.
View our earnings forecast for Repligen
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) posted its earnings results on Wednesday, April, 27th. The biotechnology company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.20. The biotechnology company had revenue of $206.40 million for the quarter, compared to analyst estimates of $185.48 million. Repligen had a trailing twelve-month return on equity of 11.13% and a net margin of 19.86%. The firm's revenue was up 44.5% on a year-over-year basis. During the same quarter last year, the company earned $0.68 EPS.
View Repligen's earnings history
.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided EPS guidance of $3.07-3.15 for the period, compared to the consensus estimate of $3.25. The company issued revenue guidance of $770-800 million, compared to the consensus revenue estimate of $820.31 million.

What price target have analysts set for RGEN?

6 equities research analysts have issued 1 year price objectives for Repligen's stock. Their forecasts range from $250.00 to $335.00. On average, they expect Repligen's share price to reach $301.50 in the next twelve months. This suggests a possible upside of 95.1% from the stock's current price.
View analysts' price targets for Repligen
or view top-rated stocks among Wall Street analysts.

Who are Repligen's key executives?
Repligen's management team includes the following people:
What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.99%), Invesco Ltd. (3.23%), WCM Investment Management LLC (2.56%), State Street Corp (2.54%), Select Equity Group L.P. (1.73%) and Bank of New York Mellon Corp (1.56%). Company insiders that own Repligen stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen
.

Which major investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including 1832 Asset Management L.P., Gilder Gagnon Howe & Co. LLC, The Manufacturers Life Insurance Company , First Trust Advisors LP, National Bank of Canada FI, Vanguard Group Inc., SG Americas Securities LLC, and Americana Partners LLC. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, and Thomas F Ryan Jr.
View insider buying and selling activity for Repligen
or view top insider-selling stocks.

Which major investors are buying Repligen stock?

RGEN stock was acquired by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Echo Street Capital Management LLC, Natixis Advisors L.P., Bank of New York Mellon Corp, Royce & Associates LP, Farallon Capital Management LLC, Congress Asset Management Co. MA, and Invesco Ltd..
View insider buying and selling activity for Repligen
or or view top insider-buying stocks.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $154.53.

How much money does Repligen make?

Repligen has a market capitalization of $8.41 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.529990 on an earnings per share basis.

How many employees does Repligen have?

Repligen employs 1,852 workers across the globe.

Does Repligen have any subsidiaries?

The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.

When was Repligen founded?

Repligen was founded in 1981.

What is Repligen's official website?

The official website for Repligen is www.repligen.com.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at (781) 250-0111, via email at [email protected], or via fax at 781-250-0115.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.